Results 61 to 70 of about 54,904 (251)

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

open access: yesOncoImmunology, 2018
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy.
Renée C. G. de Bruin   +16 more
doaj   +1 more source

Unions: Rent Extractors or Creators? [PDF]

open access: yes, 2004
Unions: Rent Extractors or ...
Aidt, Toke S., Sena, Vania
core   +1 more source

ZNRD2 Mediated Nucleoprotein Aggregation Impairs Respiratory Syncytial Virus Replication

open access: yesAdvanced Science, EarlyView.
During RSV infection, nucleoprotein (N) forms RNA‐bound oligomers. The host protein ZNRD2 binds to these oligomers, promoting their transition into insoluble aggregates. These aggregates simultaneously sequester functional N to restrict viral production and disrupt chaperonin assembly quality control by interfering with ZNRD2's role as an adaptor ...
Haiwu Zhou   +8 more
wiley   +1 more source

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

open access: yesAdvanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li   +8 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

A novel single-domain antibody multimer that potently neutralizes tetanus neurotoxin

open access: yesVaccine: X, 2021
Tetanus antitoxin, produced in animals, has been used for the prevention and treatment of tetanus for more than 100 years. The availability of antitoxins, ethical issues around production, and risks involved in the use of animal derived serum products ...
Hans de Smit   +4 more
doaj   +1 more source

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

open access: yesAdvanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen   +7 more
wiley   +1 more source

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes

open access: yesAntibodies, 2019
Broad and potent neutralizing llama single domain antibodies (VHH) against HIV-1 targeting the CD4 binding site (CD4bs) have previously been isolated upon llama immunization.
Nika M. Strokappe   +9 more
doaj   +1 more source

Progressive vowel height harmony in Proto-Kikongo and Proto-Bantu [PDF]

open access: yes, 2019
The systematic comparison of the different types of progressive Vowel Height Harmony (pVHH) attested within the Kikongo Language Cluster (KLC) leads to the conclusion that this common Bantu process of long-distance assimilation cannot be reconstructed to
Bostoen, Koen, Goes, Heidi
core   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy